DISEASE & MANAGEMENT
Accommodative (Focusing) Dysfunctions
Contact Lens & Eyeware
Convergence Excess (BV Disorder)
Convergence Insufficiency (BV Disorder)
Eyelid Bump / Swelling
Eye Pain or Eyelid Pain
Flashes or Floaters in Vision
Glasses & Eyeware
Ischemic Optic Neuropathy
Loss of Vision
Retinal Tear & Detachment
Strabismus & Amblyopia
Traumatic Brain Injury
Corneal cross-linking was FDA approved in April 2016.
It is a minimally invasive procedure that combines the use of Vitamin B2 eye drops and ultra-violet (UV) light to help strengthen corneal tissue that has been weakened by disease.
Normal corneas have crosslinks within their collagen fibers to keep it strong and able to retain its shape.
In keratoconus, the cornea is weak with insufficient support.
Corneal cross-linking works by increasing the collagen crosslinks which are the natural “anchors” within the cornea. These anchors are responsible for preventing the cornea from bulging out and becoming steep and irregular.
While cross-linking is not a cure for keratoconus, it may slow the progression of the disease, making the cornea more stable.
It may also make contact lens fitting easier, but may not completely correct your vision or eliminate the need for glasses and/or contact lenses.
Corneal cross-linking inhibits the progression or corneal ectasia and keratoconus.
It may be combined with Intacs® and photoablation.
The goal of the procedure is to treat at diagnosis versus wait for progression.
Over 14 years old with progression
None to minimal corneal scarring
Maximum Keratometry reading of <60 Diopters
Corneal Pachymetry > 400 microns
Active herpetic disease
Corneal Pachymetry <400 microns
History of poor healing
Active ocular infection
Severe ocular surface disease
Severe corneal scarring
SERVICE AREAS PROVIDING TREATMENT
Cornea Center for Clinical Excellence